Claims Using Naturally-Occurring Phenomenon in Method of Preparation Found Patent Eligible
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
ILLUMINA, INC. v. ARIOSA DIAGNOSTICS, INC.
Before Lourie, Moore, and Reyna. Appeal from the Northern District of California.
Summary: Use of a natural phenomenon in a method of preparation claim found patent eligible under § 101.
Illumina, Inc. (“Illumina”) sued Ariosa Diagnostics, Inc. (“Ariosa”) alleging infringement of patents directed to methods of extracting fetal DNA from the blood of a pregnant woman based on the size difference between fetal DNA and maternal DNA. The District Court for the Northern District of California granted summary judgment in favor of Ariosa, ruling that Illumina’s patents were invalid under 35 U.S.C. § 101 as being directed to a natural phenomenon.
Illumina appealed and the Federal Circuit reversed finding that Illumina’s patents were directed to patent-eligible subject matter. The Court acknowledged that Illumina discovered a natural phenomenon (e.g., the difference in size between fetal and maternal DNA), but concluded that Illumina’s claims were not directed to the natural phenomenon. Rather, the Federal Circuit found the claims were directed to methods that utilize the natural phenomenon (e.g., separation of the fetal DNA based on size using centrifugation, chromatography, electrophoresis, or nanotechnology).
Judge Reyna dissented.
Editor: Paul Stewart
Written by: David C, O'Hair & Christie Matthaei
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…